 Irish Times | Biogen Idec Management Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha We expect data readouts for daclizumab in 2014, TYSABRI and SPMS in 2015 and potentially SMNrx in 2016. During that time frame, we expect to have meaningful data readouts from our Phase II compounds and proof-of-concept data from several other ... Biogen Idec Total Revenues Increased 10% to $1.4 Billion in First Quarter 2013 |
